Technology area: Biotechnology & Pharmaceuticals
200 pending office actions • 77 clients • 174 examiners • 73 art units • 0 of 200 (0%) have an AI response strategy ready • 163 patents granted in the last 365 days
pH IP Law handles Biotechnology & Pharmaceuticals matters and has 197 pending office actions. Its career application record includes 6778 applications, placing the active workload within a broad historical prosecution record.
The resolved allowance rate is 79.46%, and the average office actions per allowance is 3.89. The rate describes outcomes among resolved applications, while the action average indicates the examination activity associated with allowed matters. Practitioners can use these measures to evaluate current response demands alongside the firm’s recorded approach to biotechnology and pharmaceutical prosecution.
Based on the USPTO statutory response window for each pending office action. 68 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 68 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 15 (8%) |
| §103 only | 49 (24%) |
| §102 only | 3 (2%) |
| §112 only | 19 (10%) |
| Double-patenting only | 4 (2%) |
| Double-patenting + other | 30 (15%) |
| Multi-statute (no §101) | 77 (38%) |
| No statute on record | 3 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, WILLIAM A | 3 | 48.9% | +38.1% |
| NGUYEN, QUANG | 3 | 37.9% | +52.6% |
| GEMBEH, SHIRLEY V | 2 | 63.1% | +33.8% |
| BERTOGLIO, VALARIE E | 2 | 64.1% | +30.3% |
| KNIGHT, TERESA E | 2 | 66.1% | +48.1% |
| HOERNER, PAUL ELLSWORTH | 2 | 50.6% | +62.3% |
| NGUYEN, NGHI V | 2 | 53.6% | +50.8% |
| VANHORN, ABIGAIL LOUISE | 2 | 46.8% | +22.7% |
| RAHMAN, MASUDUR | 2 | 72.9% | +31.7% |
| SALMON, KATHERINE D | 2 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | VYAS, KEYUR ANILKUMAR | 87d overdue |
| 17429182 | CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES | FAY, ZOHREH ALEMZADEH | 73d overdue |
| 17693062 | METHODS TO PREPARE DRY POWDERS USING SUSPENSION BASED THIN FILM FREEZING | GOTFREDSON, GAREN | 60d overdue |
| 18873924 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | MCCULLOUGH, ERIC J. | 42d overdue |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | ADAMS, MICHELLE | 42d overdue |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | SALMON, KATHERINE D | 28d overdue |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | BUTTICE, AUDREY L | 28d overdue |
| 18017669 | USE OF PERLECAN AND FRAGMENTS THEREOF TO REDUCE THE RISK OF DEATH IN STROKE PATIENTS | STEELE, AMBER D | 28d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | SALMON, KATHERINE D | 161d overdue |
| 16933773 | NUCLEIC ACID PURIFICATION | NGUYEN, QUANG | 100d overdue |
| 16098145 | IMPROVED DRUG FORMULATIONS | CRAIGO, WILLIAM A | 98d overdue |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | SALMON, KATHERINE D | 28d overdue |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 17819268 | DRY LIPOSOME FORMULATIONS AND RELATED METHODS THEREOF | HOERNER, PAUL ELLSWORTH | 4d overdue |
| 18271294 | DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT | RAHMAN, MASUDUR | 27d |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | GEMBEH, SHIRLEY V | 70d |
| Art Unit | Apps |
|---|---|
| 1682 | 8 |
| 1615 | 7 |
| 1631 | 7 |
| 1632 | 7 |
| 1636 | 6 |
| 1658 | 6 |
| 1637 | 6 |
| 1644 | 6 |
| 1675 | 5 |
| 1616 | 5 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19461491 | Untitled | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | MIDDLETON, DANAYA L | §103§112 | Non-Final OA | — | Pending | ||
| 19637493 | JELLYFISH COLLAGEN USE | Jellagen Limited | MELLER, MICHAEL V | 1655 | §103 | Non-Final OA | — | Pending | Apr 02, 2026 |
| 19363455 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | Curevac Manufacturing GmbH | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Oct 20, 2025 |
| 19118598 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY | ROY, BAISAKHI | 3797 | §101§103§112 | Non-Final OA | — | Pending | Apr 04, 2025 |
| 19083757 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | Rein Therapeutics, Inc. | GEMBEH, SHIRLEY V | 1615 | DP | Non-Final OA | — | Pending | Mar 19, 2025 |
| 19110271 | COMPOSITION FOR ENHANCING IMMUNITY | Kolmar Bnh Co., Ltd. | SPAINE, ROBERT FRANKLIN | 1655 | §101§103§112 | Non-Final OA | — | Pending | Mar 10, 2025 |
| 19052850 | ELECTRIC-FIELD DIRECTED NERVE REGENERATION | UNIVERSITY OF SOUTHERN CALIFORNIA | LEE, BRYAN MCALLISTER | 3796 | §101§103 | Non-Final OA | — | Pending | Feb 13, 2025 |
| 19042229 | DEVICES, SYSTEMS AND METHODS FOR CLEANING OF ELONGATED INSTRUMENT SURFACE | Ascension Texas | HENDERSON, RYAN N | 3795 | §102§112Other | Non-Final OA | — | Pending | Jan 31, 2025 |
| 19002848 | METHODS FOR OPTIMIZING THE PLANNING AND PLACEMENT OF PROBES IN THE BRAIN VIA MULTIMODAL 3D ANALYSES OF CEREBRAL ANATOMY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | WILBURN, MOLLY K | Other | Non-Final OA | — | Pending | Dec 27, 2024 | |
| 18980005 | SYSTEMS AND METHODS FOR CORONARY OCCLUSION TREATMENT | Research Development Foundation | LAU, MICHAEL J | 3796 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18873924 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | The Board Of Regents Of The University Of Oklahoma | MCCULLOUGH, ERIC J. | 1773 | §103§112 | Final Rejection | 42d overdue | Pending | Dec 11, 2024 |
| 18872223 | APOMORPHINE PRODRUGS AND USES THEREOF | Ever Neuro Pharma GmbH | BRAUN, MADELINE E | 1629 | §103§112 | Non-Final OA | — | Pending | Dec 05, 2024 |
| 18858186 | REAL-TIME BREATH ADAPTIVE NEBULIZER APPARATUS AND METHODS FOR PULMONARY THERAPEUTIC AGENT DELIVERY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ALBERS, KEVIN S | 3786 | §103§112 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18857661 | MAGNETICALLY STEERABLE CATHETER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KOLKIN, ADAM D. | 3798 | §103 | Non-Final OA | 7d | Pending | Oct 17, 2024 |
| 18856686 | DELIVERY SYSTEM TO TARGET GRAM-NEGATIVE BACTERIA | The Wistar Institute | SHIAO, REI TSANG | 1691 | §112 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18856725 | DLC COATING AND PREPARATION METHOD AND DEVICE THEREFOR, COMPOSITE COATING LAYER AND COATED PRODUCT | Jiangsu Favored Nanotechnology Co., Ltd. | HORGER, KIM S. | 1717 | §103 | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18886115 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | Fujifilm Cellular Dynamics, Inc. | BERTOGLIO, VALARIE E | §101§102§112Other | Non-Final OA | — | Pending | Sep 16, 2024 | |
| 18846000 | IRREVERSIBLE ORGANIC ELECTROCHROMIC MATERIALS | UNIVERSITAET WIEN | JONES, JENNIFER ANN | 2872 | §102§103§112 | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18789888 | BIOCHEMICAL AND BIOMECHANICAL CONDITIONING FOR ENHANCING PERSONALIZED MESENCHYMAL STEM CELL THERAPIES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | KNIGHT, TERESA E | 1634 | DP | Non-Final OA | — | Pending | Jul 31, 2024 |
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | The Schepens Eye Research Institute, Inc. | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | — | Pending | Jul 27, 2024 |
| 18728949 | ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF | Case Western Reserve University | ROMERO, KRISTEN WANG | 1624 | §102§103§112 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18763115 | APPARATUS AND METHODS FOR COMPUTATIONALLY INFORMED ADHESION MEASUREMENT USING THE BLISTER TEST | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | DEVITO, ALEX T | 2855 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | Dongguk University Industry-Academic Cooperation Foundation | MCKOY, QUINCY ANDRE | 1626 | §102DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18723083 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | Suzhou Kintor Pharmaceuticals, Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18742139 | DRUG SCREENING METHOD AND MODEL FOR MONITORING PLATINUM-RESISTANT OVARIAN CANCER TUMOR GROWTH AND METASTASES | The Board Of Regents Of The University Of Oklahoma | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Final Rejection | — | Pending | Jun 13, 2024 |
| 18718892 | VACCINE PREPARATION | Hcemm Nonprofit Kft. | GRIZER, CASSANDRA SENN | 1672 | §102§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18710555 | ULTRA PH-SENSITIVE MICELLES ENCAPSULATING CYTOKINES FOR TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System | CRAIGO, WILLIAM A | 1615 | §103§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18706890 | MONOVALENT ANION SELECTIVE MEMBRANE ENABLED BY HIGH CONCENTRATION BRINE | Energy Exploration Technologies, Inc. | SPIES, BRADLEY R | §103 | Non-Final OA | — | Pending | May 02, 2024 | |
| 18649976 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | Edward Keefer | CHERNYSHEV, OLGA N | 1675 | §112DP | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18705047 | INTRA-OPERATIVELY FITTED ANTIBIOTIC SPACER SYSTEM | The Board Of Regents Of The University Of Texas System | FLORES, ADRIAN | 3774 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | GEMBEH, SHIRLEY V | 1615 | §102§103 | Final Rejection | 70d | Pending | Apr 26, 2024 |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | CUREVAC SE | MIANO, JOSEPH PAUL | 1631 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18703615 | NOVEL CRISPR/CAS13 SYSTEMS AND USES THEREOF | Casbio (S) Pte. Ltd. | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18701465 | FACILE DIRECT AMINATION AND ALKYLAMINATION OF CARBON NANOTUBES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | RHOADES, DEREK JAMES | 1692 | §102§103§112DP | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18700877 | SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS | Centre National De La Recherche Scientifique (Cnrs) | LADD, CAROLYN LOUISE | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18634454 | FORMATION OF STABLE SUBMICRON PEPTIDE OR PROTEIN PARTICLES BY THIN FILM FREEZING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DP | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | Musc Foundation For Research Development | COUNTS, GARY W | 1678 | §102§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18698615 | COMPOSITE COATING, PREPARATION METHOD, AND DEVICE | Jiangsu Favored Nanotechnology Co., Ltd. | MILLER, BETHANY MACKENZIE | 1787 | §103 | Final Rejection | 27d | Pending | Apr 04, 2024 |
| 18627146 | HYBRID GOLD NANOPARTICLE-LIPID NANOPARTICLES AND METHODS OF USE AND PRODUCTION THEREOF | The Board Of Regents Of The University Of Oklahoma | SONG, JIANFENG | 1613 | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18619514 | COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES | Research Development Foundation | ARIANI, KADE | 1651 | §103§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CUREVAC SE | HOERNER, PAUL ELLSWORTH | 1611 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18585375 | TRANSCRIPTION TERMINATOR BIOPARTS BASED ON 3'-UNTRANSLATED REGION (UTR) AND A METABOLIC ENGINEERING METHOD THEREOF | Korea Advanced Institute Of Science And Technology | REGLAS, GEORGIANA C | 1656 | §101§102§103 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | Curevac Manufacturing GmbH | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18436313 | SYSTEMS AND METHODS FOR STRESS DETECTION USING KINEMATIC DATA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | PHUNG, STEVEN HUYNH | 2125 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | Curevac Manufacturing GmbH | ADAMS, MICHELLE | 1797 | §103§112 | Final Rejection | 42d overdue | Pending | Feb 05, 2024 |
| 18292366 | IMPROVED DRUG PROCESSING METHODS TO INCREASE DRUG LOADING | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | SAEED, ALI S | 1616 | §103DP | Non-Final OA | 10d overdue | Pending | Jan 26, 2024 |
| 18291318 | MYOGENIC PROGENITOR CELLS FOR USE IN AN OPTIMIZED METHOD FOR THE PREVENTION AND TREATMENT OF ANAL INCONTINENCE | Innovacell GmbH | NGUYEN, NGHI V | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18419370 | COMPOSITIONS, METHODS AND USES FOR TREATING CYSTIC FIBROSIS AND RELATED DISORDERS | The Board Of Regents Of The University Of Texas System | VANHORN, ABIGAIL LOUISE | 1636 | §103§112Other | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC SE | BERTOGLIO, VALARIE E | 1632 | §103§112 | Non-Final OA | 11d overdue | Pending | Jan 17, 2024 |
| 18413541 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS | Research Development Foundation | PAGUIO FRISING, MICHELLE F | 1651 | §103DP | Non-Final OA | 84d | Pending | Jan 16, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial79.5% of resolved applications prosecuted by Ph Ip Law were allowed, across 6,778 applications in USPTO records.
3.89 office actions per allowed application on average.
200 pending office actions as of October 2026, for 77 clients, before 174 examiners in 73 art units.
